You are here

Information about licensing CRISPR genome editing systems

Broad Institute, MIT, and Harvard share the goal of developing innovative technologies such as our CRISPR genome editing tools and promoting translation to benefit patients. We are committed to making these technologies broadly available for research to help ensure that therapeutic development — bringing this technology to the clinic — has the best chance of success.

Our mission: Sharing technology to benefit research

Broad Institute is an academic non-profit research organization. Our faculty develop innovative techniques, create analytical tools, and make groundbreaking discoveries that we share with the global scientific community to benefit human health.

Broad Institute, MIT, and Harvard University partners have made CRISPR technology broadly available to the research community. Broad Institute is working with Addgene, a non-profit plasmid repository, to offer Zhang lab CRISPR plasmids and reagents to accelerate academic research. As of November 2016, Addgene had shared more than 36,000 reagents with users worldwide. In addition, we have non-exclusively licensed many industry partners for development of research tools and reagents and will continue to do so. 

To inquire about CRISPR licensing opportunities, please send an email to

If you are a journalist inquiring about CRISPR patent and licensing issues, please email and visit our CRISPR patent background page.

Additional resources